Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: oral biotherapeutics - Precigen Inc

Drug Profile

Research programme: oral biotherapeutics - Precigen Inc

Alternative Names: AG015; Antibody-toxin conjugates - Precigen Inc; Clostridium difficile enteropathy therapeutic - Precigen Inc; Clostridium difficile-associated enterocolitis therapeutic - Precigen Inc; IL-10/proinsulin ActoBiotics™; IL-27 - Precigen Inc; Inflammatory bowel disease ActoBiotics™; Inflammatory bowel disease therapeutics - Precigen Inc; Interleukin-27 - Precigen Inc; Lactococcus lactis expressing human interleukin-27; Lactococcus lactis secreting human interleukin-27; Microbiome ActoBiotics™; Microbiome modulators - Precigen Inc; Microbiota ActoBiotics™; Microbiota modulators - Precigen Inc; Peptide-toxin conjugates - Precigen Inc

Latest Information Update: 28 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ActoGeniX
  • Developer Intrexon Corporation; Precigen Inc; Theriva Biologics
  • Class Anti-inflammatories; Antigens; Antihyperglycaemics; Bacteria; Cytokines; Hormones; Monoclonal antibodies; Peptides; Recombinant proteins; Small molecules
  • Mechanism of Action Bacterial toxin inhibitors; Enzyme replacements; Helper-inducer T-lymphocyte modulators; Immunomodulators; Immunosuppressants; Interleukin 27 replacements; Microbiome modulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Coeliac disease; Type 1 diabetes mellitus

Highest Development Phases

  • No development reported Digestive system disorders; Inflammatory bowel diseases; Non-alcoholic steatohepatitis; Phenylketonuria; Type 2 diabetes mellitus
  • Discontinued Clostridium difficile infections

Most Recent Events

  • 28 Nov 2022 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA (PO)
  • 12 Oct 2022 Synthetic Biologics is now called Theriva Biologics
  • 28 Mar 2022 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in Belgium (PO, Capsule)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top